What's Happening?
Sanofi has received approval in the UK for its subcutaneous formulation of the multiple myeloma drug Sarclisa, marking the UK as the first market for this on-body injector (OBI) version. The new Sarclisa product, which utilizes the CirCLIQ OBI device,
is designed to compete with Johnson & Johnson and Genmab's Darzalex, which significantly outsold Sarclisa last year. Both drugs are available in intravenous forms, but the subcutaneous version of Darzalex, known as Darzalex Faspro, was approved in 2020. Sanofi's OBI device aims to offer a more patient-friendly treatment experience, allowing for flexible administration in home or outpatient settings. The device uses a hidden, retractable needle to deliver high volumes of subcutaneous therapies, drawing on technology developed by Enable Injections. This innovation is expected to reduce the burden of repeated clinic visits for patients with multiple myeloma.
Why It's Important?
The approval of Sanofi's subcutaneous Sarclisa represents a significant advancement in the treatment of multiple myeloma, a complex disease that often requires frequent and prolonged clinic visits. By enabling administration at home or in outpatient settings, the new formulation could alleviate the burden on healthcare systems and improve patient quality of life. This development aligns with broader healthcare objectives, such as the NHS 10-Year Plan and National Cancer Plan, which aim to transform healthcare delivery through technology. The introduction of the OBI device could also enhance patient comfort and satisfaction, potentially leading to better adherence to treatment regimens and improved outcomes.
What's Next?
Sanofi's subcutaneous Sarclisa is expected to be launched in the UK market soon, with potential expansion to other regions pending regulatory approvals. The company is awaiting a decision in the US, which is expected next month. As the first anticancer treatment administered via an OBI, Sarclisa could set a precedent for future innovations in cancer treatment delivery. Healthcare providers and patients will likely monitor the effectiveness and convenience of this new treatment option closely, which could influence its adoption and integration into standard care practices.
Beyond the Headlines
The introduction of the subcutaneous Sarclisa could have broader implications for the pharmaceutical industry, particularly in the development and delivery of cancer treatments. The use of on-body injectors may become more prevalent, offering a new standard for patient-centered care. This shift could drive further innovation in drug delivery technologies, potentially leading to more personalized and convenient treatment options across various therapeutic areas.
